Table 6.
Patents protecting combinations comprising at least one ICI
| Lead compound | target/function | combination with | company | key patent publication | clinical trial |
|---|---|---|---|---|---|
| Biotech/Universities | |||||
| BBI608 | STAT3 pathway inhibitor | Ipilimumab (anti CTLA-4) Nivolumab, Pembrolizumab (anti PD-1) | Boston Biomedical | US8877803 | NCT02467361 |
| PV10 | Rose Bengal disodium | systemic immunomodulators, like CTLA-4 | Pfizer+Provectus | WO2012122444 | |
| GR-MD-02 | galectin inhibitor | Ipilimumab | Galectin | US2014086932 | NCT02117362 |
| Inhibitor of kyurenine degradation, or kynurenine analogue | Kynurenine Monooxygenase inhibitor, e.g., Ro 61-8048 | checkpoint inhibitors | ImmusMol | not yet published | |
| vemurafenib | PLX4032, small molecule inhibitor of mutated BRAF | anti PD-1 or anti CTLA-4 after genomic testing | Emory Univ | US20140147411 | NCT01656642 |
| dabrafenib | L01XE23, small molecule inhibitor of mutated BRAF | anti CTLA-4 +/− trametinib | NCT01767454 | ||
| pembrolizumab (anti PD-1) +/− trametinib | NCT02130466 | ||||
| durvalumab (anti PD-1) +/− trametinib | NCT02027961 | ||||
| Large Pharma inhouse | |||||
| mek inhibitor | anti PD-1/anti PD-L1 | Genentech | WO2013019906 | ||
| dinaciclib | CDK inhibitor | anti-PD-1/anti-PD-L1 | Merck&Co | WO2015026634 | |
| nivolumab | anti-PD-1 | ipilimumab (anti-CTLA-4) | BMS | WO2013173223 | NCT01844505 |
| nivolumab | anti-PD-1 | HER2/neu (ErbB2) | Roche | WO201483178 | |
| Indolinone | receptor tyrosine kinase inhibitor | anti-CTLA-4 (tremelimumab or ipilimumab) | Pfizer | US20090074787 | |
| mek inhibitor | pd-1 axis binding antagonists, e.g., anti PD-L1 antibody MPDL3280A | Genentech | WO2013019906 | ||
| etposide | anti-CTLA-4 (tremelimumab or ipilimumab) | BMS | US8685394 | NCT0145076 | |
| dacarbazine | anti-CTLA-4 (tremelimumab or ipilimumab) | BMS | US20130064831 | NCT00324155 | |
| ixabepilone | tubulin inhibitor | anti-CTLA-4 (ipilimumab) | BMS | US8449886 | |
| Large Pharma/Large Pharma | |||||
| mogamulizumab | anti CCR4 | nivolumab (anti-PD-1) | Kyowa Hakko Kirin+BMS | Tbd | NCT02301130 |
| mogamulizumab | anti CCR4 | tremelimumab (anti CTLA-4) | Kyowa Hakko Kirin+AstraZeneca | Tbd | |
| HSV/TVEC | Talimogene laherparepvec (TVEC, engineered from HSV1) | anti-CTLA-4 | Amgen+BMS | WO2014036412 | |
| pembrolizumab (PD-1) | Amgen+Pfizer | NCT02263508 | |||